-
Headquarter-R/D Center
01"The Headquarter, located in Shenzhen, China, serves as the Research and Development Center of Hybio Pharmaceutical Co., Ltd. and is a pivotal part of our commitment to peptide research, employing a team of 160 talented scientists and researchers. This facility is actively involved in setting standards for peptide-based medications, contributing in drafting 49 items to national industrial standard for peptide drugs. The center's infrastructure is marked by a thoughtful investment in technology, with a well-equipped laboratory space that facilitates both groundbreaking research and the scale-up of production processes. The presence of over 300 pieces of modern equipment underscores our capacity for innovation and precision in drug development. -
API Center (Wuhan)
02Hybio Pharmaceutical (Wuhan) Co., Ltd. is a wholly-owned subsidiary of Hybio Pharmaceutical Co. Ltd. and it serves as the API production center for Hybio. It is a testament to our dedication to manufacturing excellence. Adhering to the highest cGMP standards and US FDA approval, this facility spans an impressive 100 acres and includes six workshops designed for the efficient production of polypeptide APIs. The site's ability to produce large quantities of APIs is matched by its international certifications, reflecting a commitment to quality that meets the rigorous standards of regulatory bodies worldwide. This facility plays a crucial role in ensuring the reliable supply of high-quality ingredients for pharmaceutical products. -
FDF Center (Pingshan)
03Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) serves as the Finished Dosage Form (FDF) Production Center for Hybio and it represents our capabilities in producing final pharmaceutical products. Constructed according to top international cGMP guidelines, this facility covers a substantial area and is equipped with the latest production technology. The site's design and operation have been recognized with new GMP certification and US FDA approval, affirming our adherence to the highest standards of pharmaceutical manufacturing. The advanced production lines here are integral to our mission of delivering safe and effective medicines to patients globally. -
CBD Center
04Located in the Dali Economic Development Zone, the Hybio Biotechnology facility serves as the CBD center for Hybio and it focused on the innovative processing of industrial hemp. This joint venture is a strategic move towards sustainable biotechnology, aiming to broaden our product portfolio through advanced research and development. The facility's design and operation reflect a commitment to environmental sustainability and innovation, contributing to the advancement of pharmaceutical biotechnology. By fostering collaborations across academia, government, and the industry, we aim to leverage collective expertise for the betterment of pharmaceutical sciences. -
Medical Device and OSD Center
05Gansu ChanGee Bio-Pharmaceutical Co., Ltd, a wholly-owned subsidiary of Hybio Pharmaceutical Co. Ltd, focuses on the production and sales of formulations and medical devices for the domestic market. It holds both Drug Production License and Medical Equipment Production License, demonstrating its commitment to quality and compliance. The company's facilities extend over approximately 78.5 acres, emphasizing environmental sustainability with nearly half of the area dedicated to green spaces. With a registered capital of 229 million Yuan and 67 patented technologies, Gansu ChanGee has secured new GMP certifications and possesses 171 national drug approval numbers, along with 9 medical device registration certificates. The company boasts 10 production lines, specializing in a wide range of therapeutic areas including oncology, cardiovascular diseases, antibiotics, diabetes management, and innovative medical devices for drug delivery.